RUA Life Sciences plc
RUA Life Sciences plc (formerly AorTech International, registered in Scotland, company number SC170071) is a medical device group specialising in implantable textiles and biostable polymers. It develops and licenses device-related IP (notably the Elast-Eon polyurethane and AurTex composite), develops and manufactures components and finished devices under contract for customers (Medical Devices and Components, including its Abiss France/Poland subsidiaries), and is developing its own vascular graft and polymeric heart valve products. Revenue is generated through Biomaterials licensing/royalties and Contract Manufacture/Medical Devices & Components; Vascular and Structural Heart are earlier-stage development areas.
FY2025 in sixty seconds
year to 30 Sept 2025 · approved 29 Jan 2026 · 96 pages · Companies House
RUA Life Sciences makes and licenses materials and parts for implanted medical devices. Revenue rose to £6.7m from £2.2m, and the loss before tax narrowed to £236k from £2.0m. This report covers 18 months, against 12 months the year before, so the figures are not directly comparable.
Most growth came from making devices and parts for other companies, helped by buying the French firm Abiss in September 2024. The result was flattered by a one-off £0.9m non-cash gain from buying Abiss for less than its assets were worth; without it, the loss before tax was £1.1m. Lower research spending and fewer senior roles cut costs.
Cash at the period end was £3.2m, down from £3.9m, and borrowings were £73k. No money was raised from shareholders and no dividend was proposed. Management says its goals of doubling revenue and using less cash were met early, and it plans further growth. The auditor raised no concerns and the directors found no doubt about the company continuing to trade, though the report warns of growing reliance on a few large customers.
Contract Design & Manufacture of medical devices/components (Medical Devices & Components segment, incl. Abiss)
Segment revenue £5,759k of £6,689k total (86% of Group revenue); UK operations £3.6m (53%, 41% like-for-like growth), EU/Abiss £2.2m (33%, new contribution)
page 10Gross margin from contract manufacturing and licensing
Gross profit £5,251k on revenue £6,689k (c.78.5% gross margin)
page 56The two year objectives set at the time of the 2023 Strategy Review, of doubling revenues, reducing cash burn and focussing on profitability have been achieved ahead of time through strong trading and the purchase of the Abiss subsidiary in France. We look forward to building upon this success through broadening both services for current customers and expanding the customer base further.
page 5No dividends have been proposed for the period ended 30 September 2025 (2024: £nil); Group is primarily funded by equity finance and is not yet in a position to pay a dividend.
page 1211 years on one page · FY2015–FY2025
| Line | FY2015locked | FY2016locked | FY2017locked | FY2018locked | FY2019locked | FY2020locked | FY2021locked | FY2022locked | FY202303/23 | FY202403/24 | FY202509/25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||
| Operating profit | |||||||||||
| Profit for the year | |||||||||||
| Basic EPS | |||||||||||
| Dividend per share | |||||||||||
| Free cash flow | |||||||||||
| Net debt (negative = net cash) | |||||||||||
| Shares in issue | |||||||||||
| Operating margin | |||||||||||
| Return on capital employed |
GBP millions, negatives in brackets. Per-share lines in pence. Share counts in millions. Margins and returns as percentages, calculated from the filed figures. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated.
20 figures restated in a later report
Every figure is read again from the following year’s report: 290 confirmed, 14 differ, 20 restated.
No figure has been restated: every figure a later report printed again, it printed the same.
20 more figures were restated in FY2015 to FY2022, which a free account opens.